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Neurobiology of Disease
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1Department of Neurobiology and 2Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15260, 3Michigan
State University, College of HumanMedicine, Department of Translational Science and Molecular Medicine and The Udall Center of Excellence in
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The striatum is essential for many aspects of mammalian behavior, including motivation andmovement, and is dysfunctional in motor
disorders such as Parkinson’s disease. The vesicular glutamate transporter 3 (VGLUT3) is expressed by striatal cholinergic interneurons
(CINs) and is thus well positioned to regulate dopamine (DA) signaling and locomotor activity, a canonical measure of basal ganglia
output. We now report that VGLUT3 knock-out (KO) mice show circadian-dependent hyperlocomotor activity that is restricted to the
waking cycle and is due to an increase in striatal DA synthesis, packaging, and release. Using a conditional VGLUT3 KOmouse, we show
that deletion of the transporter from CINs, surprisingly, does not alter evoked DA release in the dorsal striatum or baseline locomotor
activity. The mice do, however, display changes in rearing behavior and sensorimotor gating. Elevation of DA release in the global KO
raised the possibility that motor deficits in a Parkinson’s disease model would be reduced. Remarkably, after a partial
6-hydroxydopamine (6-OHDA)-mediated DA depletion (70% in dorsal striatum), KO mice, in contrast to WT mice, showed normal
motor behavior across the entire circadian cycle. L-3,4-dihydroxyphenylalanine-mediateddyskinesiaswere also significantly attenuated.
These findings thus point to new mechanisms to regulate basal ganglia function and potentially treat Parkinson’s disease and related
disorders.
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Significance Statement
Dopaminergic signaling is critical for bothmotor and cognitive functions in themammalian nervous system. Impairments, such
as those found in Parkinson’s disease patients, can lead to severe motor deficits. Vesicular glutamate transporter 3 (VGLUT3)
loads glutamate into secretory vesicles for neurotransmission and is expressed by discrete neuron populations throughout the
nervous system. Here, we report that the absence of VGLUT3 inmice leads to an upregulation of the midbrain dopamine system.
Remarkably, in a Parkinson’s disease model, the mice show normal motor behavior. They also show fewer abnormal motor
behaviors (dyskinesias) in response to L-3,4-dihydroxyphenylalanine, the principal treatment for Parkinson’s disease. The work
thus suggests new avenues for the development of novel treatment strategies for Parkinson’s disease and potentially other
basal-ganglia-related disorders.
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Introduction
Basal ganglia circuits are important formotor planning, learning,
and motivation. Within the basal ganglia, the striatum receives
major cortical and thalamic glutamatergic input, as well as a
dense innervation from midbrain dopamine (DA) neurons.
These inputs converge onto striatal medium spiny neurons
(MSNs), the major output neurons. Also shaping striatal output
are a number of interneurons, including cholinergic interneu-
rons (CINs), also referred to as tonically active neurons, which
are sparse but form a dense arborization and are temporally
aligned with the activity of DA neurons.
The striatum is also central to a number of neurodegenerative
disorders, including Parkinson’s disease, which is characterized
by a loss of substantia nigra pars compacta DA neurons that
project to the dorsal striatum. This loss produces motor deficits
such as rigidity, tremor, altered gait, bradykinesia, and dysphagia.
Treatments for the disorder have included anticholinergic
drugs (Gomeza et al., 1999) and the DA precursor L-3,4-
dihydroxyphenylalanine (L-dopa). However, side effects make
these therapies difficult to tolerate, including unwanted motor
movements known as dyskinesias, which often arise from esca-
lating doses of L-dopa (Zhuang et al., 2013). New approaches to
the treatment of Parkinson’s disease are thus still of great interest.
Vesicular glutamate transporter isoform 3 (VGLUT3) is one
of three proteins that packages glutamate into secretory vesicles
for regulated release (Fremeau et al., 2002; Gras et al., 2002;
Scha¨fer et al., 2002;Gras et al., 2008; Seal et al., 2008). VGLUT1or
VGLUT2 is present at most excitatory nerve terminals, whereas
VGLUT3 has a more discrete expression pattern. Within the
striatum, cholinergic interneurons express the transporter
(Fremeau et al., 2004) and, interestingly, VGLUT3-mediated
cotransport of glutamate enhances vesicular acetylcholine (ACh)
content (Gras et al., 2008). Therefore, deletion of VGLUT3 from
these cells not only abolishes the glutamate signaling (Higley et
al., 2011), but also markedly reduces cholinergic transmission
(Nelson et al., 2014).However, the role of the glutamate signaling
remains unclear.
It was reported previously that VGLUT3 KO mice are hyper-
locomotive (Gras et al., 2008), a phenotype that is often associ-
atedwith increasedmidbrainDA signaling and is thus potentially
relevant to other basal-ganglia-related behaviors such as reward,
movement, memory, and motivation. Given the classically as-
sumed antagonistic relationship between striatal acetylcholine
and DA (DeBoer et al., 1996; Ding et al., 2006; Surmeier and
Graybiel, 2012), it was suggested that the low vesicular ACh tone
in CINs of the KO could lead to dysregulation of DA signaling
and hyperlocomotor activity. However, specific deletion of the
vesicular acetylcholine transporter (VAChT) in cholinergic in-
terneurons hadno effect on baseline locomotor activity (Guzman
et al., 2011), raising the possibility that loss of CIN-mediated
glutamate signaling causes DA dysregulation and hyperlocomo-
tor activity.
Using a combination of electrophysiology, histology, bio-
chemistry, and behavior, we now show that VGLUT3 KO mice
are markedly hyperlocomotive only during the waking cycle.
Consistent with this, striatal DA synthesis and release are also
significantly elevated only during this time. In addition, using a
conditional VGLUT3 KOmouse, we rule out the possibility that
the loss of glutamate signaling by cholinergic interneurons serves
as the basis for the upregulation of the midbrain DA system.
Deletion of VGLUT3 in cholinergic neurons does, however, in-
terfere with sensorimotor gating and habituation of rearing. Be-
cause increased striatal DA and decreased ACh signaling have
therapeutic implications for Parkinson’s disease, we investigated
whether the KOmice would show reduced motor symptoms in a
model of the disease and, indeed, the mice lacked the motor
deficits normally caused by DA depletion and also showed a
marked attenuation of L-dopa-mediated dyskinesias.
Materials andMethods
Animals.Animals were housed inmicro-isolator cages on a standard 12 h
sleep/wake cycle (7:00 A.M. lights on, 7:00 P.M. lights off). For day/night
behavioral experiments, animals were housed for at least 1 month before
testing in a separate room with a different sleep/wake cycle (1:00 A.M.
lights on, 1:00 P.M. lights off). All animals were provided ad libitum
access to food and water and were treated in compliance with Institu-
tional Animal Care andUseCommittees forUniversity of Pittsburgh and
University of California–San Francisco, with theDeclaration ofHelsinki,
and with the Institute for Laboratory Animal Research of the National
Academy of Science’s Guide for the Care and Use of Laboratory Animals
and were approved by the Institutional Animal Care andUse Committee
at Michigan State University, where L-dopa-induced dyskinesia (LID)
studies were performed, and by the Institutional Animal Care and Use
Committee at Thomas Jefferson University, where the fast-scan cyclic
voltammetry (FSCV) was conducted. All efforts were made to minimize
the number of animals used and to avoid pain or discomfort. Mice 6–24
weeks of age were used for experiments. In each experiment, approxi-
mately equal numbers of males and females of each genotype were tested
unless otherwise stated. ChAT-Cre(G) (stock #GM60Gsat) mice were
obtained from GENSAT. ChAT-IRES-Cre (stock #018957) Rosa26-FLP
(stock #003946) and Rosa26-Cre (stock #006054) mice were all obtained
from Jackson Laboratories. Slc17a8 / mice (also referred to as
Vglut3 / or VGLUT3 KO mice) mice were backcrossed at least eight
generations to C57BL/6. Mice with the conditional Vglut3 allele (i.e.,
Vglut3 fl/fl and Vglut3/) were originally derived from 129/Ola ES cells
and C57BL/6J blastocysts (described in detail below). Founders were
backcrossed three generations to C57BL/6J. Experiments were per-
formed and comparisons made only between littermates (i.e., identical
background strains): Slc17a8 /mice to their Slc17a8/ (also referred
to as Vglut3/ or WT) littermates and Slc17a8fl /fl;choline O-acetyl-
transferaseCre/ (Vglut3 fl/fl;ChatCre/) to their Cre-negative (Vglut3 fl/fl)
littermates.
To generate the conditional VGLUT3 KO mouse line (Vglut3 fl/fl), 5
and 3 arms of the targeting construct were designed to allow Cre-
dependent deletion of exon 2 of the Slc17a8 gene. This exon encodes the
first luminal loop and second transmembrane domain andwas deleted in
the global VGLUT3 KO. Arms of 2.9 kb (left) and 4.0 kb (right) were
isolated from a C57BL/6J RPCI-24 bacterial artificial chromosome clone
(BacPac) and subcloned into the targeting vector, pB6 (gift from Nirao
Shah). LoxP sites were designed around exon 2. Positive and negative
selection relied on the thymidine kinase promotor–neomyocin gene cas-
sette located between the two arms and the diphtheria toxin subunit A
gene downstream of the right arm, respectively. The final targeting plas-
mid was electroporated into 129/Ola embryonic stem (ES) cells. ES cells
Received June 2, 2015; revised Oct. 2, 2015; accepted Oct. 9, 2015.
Author contributions: C.B.D., K.S.-C., D.S., R.H.E., H.Z., and R.P.S. designed research; C.B.D., K.S.-C., D.T.C.,
S.-P.G.W., J.A.S., L.Z., C.E.S., and H.Z. performed research; C.B.D., K.S.-C., D.T.C., S.-P.G.W., M.E.R., T.J.C., H.Z., and
R.P.S. analyzed data; C.B.D. and R.P.S. wrote the paper.
The work was funded by the National Institutes of Health (Postdoctoral Training Grant T32DA031111 to C.B.D.
and National Institute of Neurological Disorders and Stroke Grant RO1 NS082650 to R.P.S.), Michigan State Univer-
sity Translational Science and Molecular Medicine Start Up Funds (T.J.C., K.S.C., and C.E.S.), the Edwin Brophy
Endowment atMichigan State University (T.J.C.), andUniversity of Pittsburgh, Department of Neurobiology Startup
Funds (R.P.S.).We thank Charlene Yuan, Natalie Cagle, and Tracy Sun for technical assistance; Shenin Dettwyler and
Chad Eckard for mouse colony maintenance; Simon Watkins for help with spine imaging; Ray Johnson and Ginger
Milne at the Vanderbilt Neurochemistry Core; Nigel Killeen at the UCSF Transgenic Core; and the Gladstone Institute
Transgenic Core.
The authors declare no competing financial interests.
Correspondence should be addressed to Rebecca P. Seal, Department of Neurobiology, University of Pittsburgh
School of Medicine, 3501 Fifth Avenue, 6058 BST3, Pittsburgh, PA 15260. E-mail: rpseal@pitt.edu.
DOI:10.1523/JNEUROSCI.2124-15.2015
Copyright © 2015 the authors 0270-6474/15/3514984-17$15.00/0
14984 • J. Neurosci., November 11, 2015 • 35(45):14983–14999 Divito et al. • VGLUT3 Affects Dopamine Function and Parkinson’s Disease
were screened by Southern blot analysis for the left and right arms to
identify founder ES cell lines. DNA was harvested from each ES cell
colony and digested overnight with BamH1 restriction enzyme (New
England Biolabs). Digested DNA was loaded onto a 0.8% agarose gel,
bands separated by gel electrophoresis and then transferred to Zeta Probe
GT Membrane (Bio-Rad Laboratories) using the alkaline capillary
method. The blot was neutralized and then incubated in prehybridiza-
tion solution for 1 h at 65°C. Probes were made using Random Primers
DNA labeling kit (Life Technologies) and  32P-labeled dCTP (3000 Ci/
mmol; PerkinElmer). Blots were hybridized overnight at 65°C, washed
4 at 65°C according to the manufacturer’s instructions, and then sub-
jected to autoradiography. ES cell founder lines were injected into pseu-
dopregnant C57BL/6J females to give rise to chimeric founders. Two
chimeric founders germline transmitted the modified Slc17a8 gene.
These founders were bred to the germline Rosa26Flp mouse to delete the
Tk-Neo gene in the germline.
To genotype for the floxed allele, primers surrounding the loxP site
(forward: atgtggatgggaaaccagaa and reverse: atagcagctggcacaccagt) were
used to generate an 300 bp band. A WT band of 260 bp can also
be detected with these primers. To detect the delta allele, primers to
sequences outside of both loxP sites were used (forward: agtccaaggtc-
ccagttggt and reverse: ctggggtactgcacctcact) to generate an 300 bp
band.
Behavior. Unless otherwise stated, both male and female mice with ages
ranging from 6 to 24 weeks were used for all behavioral analyses. Light
conditions and temperature were kept at ambient levels (32 lux, 75°F).
For home cage locomotor activity, mice were placed in rat micro-
isolator cages inside a photobeammonitoring system (Kinder Scientific)
for 48 h with ad libitum access to food and water.
For open-field analysis, mice were allowed to acclimate to the room
environment for 15 min before being placed in an open chamber (17
17 inch) with x-y-z photobeam monitoring (Motor Monitor). Ambula-
tions and rearing behavior were recorded in 1 min bins for a total of 60
min. The open field was subdivided into peripheral and center zones and
analyzed separately, but typically pooled. Mice were retested for 2 subse-
quent days at the same time of day. The open-field apparatus was also
used to measure locomotor activity for 7 h across the day/night cycle.
For the cylinder test, mice were acclimated to environment for 30 min
with food and water ad libitum. A mouse was placed in a clear acrylic
cylinder 8 cm in diameter on top of a clear acrylic sheet. The video
camera was underneath and recorded 1 5 min video per animal. The
number of contactsmadewith each forepaw against the cylinder wall was
recorded and the number expressed as a percentage of total contacts.
Only full weight-bearing contacts were counted, identified by full contact
of cylinder with majority of paw. Animals were tested 3–4 h before and
3–4 h after the start of the waking cycle on separate days.
For rotational analysis, spontaneous clockwise (CW) or counterclock-
wise (CCW) rotations, mice were placed in the open field with low light
conditions (32 lux). Mice were allowed to freely explore the chamber
and x-y beam breaks (Motor Monitor) were recorded for 15 min. Turn-
ing that broke beams in a 112° arc in either direction was scored as a
rotation.
Prepulse inhibition of acoustic startle was measured by placing mice
into a soundproof chamber (Kinder Scientific Startle Monitor). After 5
min of white noise acclimation, mice were exposed to randomized trials
of 500ms exposures to 75, 85, 95, 105, or 115 decibel sound pressure level
(dB SPL) with a 500 ms intertrial interval. For prepulse inhibition of
acoustic startle, mice were exposed to randomized trials of 80 ms of 65,
67, 69, 70, 71, 73, 75, 80, or 85 dB SPL, 280 ms before being exposed to
115 dBSPLnoises. Trials were repeated between seven and eight times for
each mouse in a randomized order. Startle was measured as the maxi-
mum force in Newtons (N) and the average response across the trial
repetitions for each mouse were used for data analysis.
Stereotaxic surgery and 6-OHDA-mediated DA depletion. Unilateral
dorsal striatal lesions were made to assess parkinsonian motor behavior.
Mice (12–24 weeks of age) were anesthetized by inhalation of 3% isoflu-
rane (Butler Schein) and surgery was performed using aseptic tech-
niques. Stereotaxic coordinates used for the unilateral injection of 6 g
6-OHDAHBr (Sigma-Aldrich) were (inmm)0.85 AP,1.75ML, and
2.75 DV. Three-minute incubation periods were used between injec-
tion needle placement, 2l injection of 6g of 6-OHDA, and removal of
the injection needle. Immediately after surgery, mice were sutured and
administered carprofen subcutaneously (Ketofen, 5 mg/kg) and allowed
to recover overnight in a heated cage with ad libitum access to water,
milled pellets mixed with water (mush), bacon softies (LBS Biotechnol-
ogy), and banana baby food (Gerber). Mice also received a subcutaneous
injection of sterile 0.9% saline (0.5 ml) 1–2 daily for 7–10 d after
surgery. Mouse weight was monitored and any that lost 20% of
their presurgical weight were excluded. No animals were lost or eutha-
nized after surgery due to complications. Animals with less than a 50%
decrease in tyrosine hydroxylase (TH) levels across the rostral-caudal
extent of the dorsal striatum were excluded from analysis (4 mice total).
Behavioral assays were performed 1–3 weeks after 6-OHDA injections.
After the behavioral testing, mice were euthanized and brains were har-
vested for TH analysis. In a subset of animals, 1.6-mm-diameter tissue
puncheswere quickly taken from the dorsal and ventral striatum (2-mm-
thick coronal section) both ipsilateral and contralateral sides, immedi-
ately frozen on dry ice, and sent for HPLC analysis of norepinephrine,
epinephrine, 3,4-dihydroxyphenylacetic acid (DOPAC), 5-hydroxyindo-
leacetic acid (5-HIAA), homovanillic acid (HVA), serotonin (5-HT), and
3-methoxytyramine (3-MT). HPLC measurements were performed by
the Vanderbilt Neurochemistry Core Facility. Residual striatal sections
(30 m thick) were used for subsequent immunohistochemical analysis
of TH levels.
For quantitation of DA tissue content, animals were euthanized at
10:00 P.M. (night) or12:00 P.M. (day), the striatum dissected on ice,
and then immediately frozen on dry ice and sent for HPLC analysis for
biogenic amines as described above.
For immunohistochemistry, mice were anesthetized with a lethal dose
of a ketamine/xylazinemixture and transcardially perfused with 25ml of
PBS, followed by 30ml of a solution of cold PBS containing the following
(in mM): 137 NaCl, 2.7 KCl, 10.1 Na2HPO4, and 1.8 KH2PO4 plus 4%
paraformaldehyde (PFA). Whole brains were dissected and incubated in
PBS 4% PFA overnight at 4°C. Brains were then cryoprotected by 3 d
incubation in 30% sucrose solution at 4°C. Brains were mounted and
sectioned into 30mslices using a cryostat (MicromHM550) andplaced
directly into wells. For fluorescent labeling, slices were incubated in PBS
containing 5% normal donkey serum (NDS) and 1% Triton X-100 for
1 h at room temperature (RT). Slices were then transferred to PBS 5%
NDS  1% Triton X-100 containing various primary antibodies (de-
scribed below) overnight at 4°C. After washing, Alexa Fluor-conjugated
secondary antibodies (Jackson ImmunoResearch) were incubated for 1 h
at RT. After washing, slices were mounted with Fluoromount-G (South-
ern Biotech) and coverslipped. Primary antibodies used consisted of
guinea pig -VGLUT3 1:2500 (Edwards Laboratory), goat -ChAT
1:1000 (Millipore), rabbit -TH 1:1000 (Millipore), mouse -glutamic
acid decarboxylase (65 kDa) 1:1000 (Millipore), and/or mouse
-glutamic acid decarboxylase (67 kDa) 1:1000 (Millipore).
For L-dopa-induced dyskinesias in rodents, severe (80%) DA deple-
tion is necessary to allow themaladaptive changes linked to LID to occur
(Cenci et al., 2002; Bastide et al., 2015). Therefore, mice were rendered
parkinsonian via unilateral stereotaxic injection of the DA neurotoxin
6-OHDA into the medial forebrain bundle (mfb). The mfb coordinates
were1.3 AP, 1.1 ML, and5.4 DV. Animals were anesthetized before
surgery with an intraperitoneal injection of ketamine/xylazine (100
mg/kg ketamine, 20mg/kg xylazine in 0.9% sterile saline; 0.1 cc/10 g) and
placed in a mouse stereotaxic frame. The 6-OHDA (5 mg of 6-OHDA
HBr/ml 0.9% sterile saline containing 0.2 mg/ml ascorbic acid) was in-
jected at a rate of 0.5 nl/min (1.5 l total) using a 5 ml Hamilton syringe
with a 26 gauge needle. Immediately after surgery, mice were adminis-
tered carprofen subcutaneously (Rimadyl, 5 mg/kg, 0.1 cc/10 g) and 0.5
ml of sterile lactated Ringer’s solution. For 1 week before surgery, mice
were acclimated to a liquefied “food slurry” (water-soaked Purina rat
chow pellets, Bioserve bacon-flavored rodent soft dough diet supple-
ment, and Gerber baby food bananas, 1:1:1). Starting the day of surgery,
mice were given food slurry, which was prepared fresh daily in a blender
and provided 2 daily (Monday through Friday) until body weights
were stable and weight gain steady. Mice also received subcutaneous
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injection of sterile 0.9% saline (0.5 ml) 1–2 daily for 7–10 d after
surgery. Survival rates were 87.5% and, of these mice, 84.3% were suc-
cessfully lesioned (DA-depletion	 93.3
 1.2%, mean
 SEM).
LIDs refer to abnormal involuntary movements including dystonia,
hyperkinesia, and/or stereotypies noted in parkinsonian mice in re-
sponse to L-dopa administered after DAdepletion by 6-OHDA lesioning.
The details of these behaviors and the rating scale used were reported
previously (Steece-Collier et al., 2003; Maries et al., 2006). To assess the
effects of knocking out VGLUT3 on LID development and expression,
mice received a daily (Monday through Friday) injection of L-dopa (1, 2,
and 3mg/kg) plus the peripheral decarboxylase inhibitor benserazide (12
mg/kg) in sterile saline over the time course depicted in Figure 9. A given
dose of L-dopa was administered for 1 week with dyskinetic behaviors
rated over the time course of LID expression (e.g., 20 to 100 min after
injection) and onMonday,Wednesday, and Friday. The same individual
who was blinded to treatment conditions and genotype performed the
LID ratings. Animals were assessed in a randomized order that was as-
signed at the beginning of the experiment and maintained for the dura-
tion. As detailed previously (Steece-Collier et al., 2003; Maries et al.,
2006), both the intensity (0 	 absent, 1 	 mild, 2 	 moderate, 3 	
severe) and frequency (0	 absent, 1	 50% of rating period, 2	 50%
of the rating period, 3 	 constant) were determined for the following
individual components of LID behavior: forelimb hyperkinesia, forelimb
dystonia, hindlimb dystonia, trunk dystonia, neck dystonia, and orolin-
gual dyskinesia. A final LID severity score for any given individual com-
ponent of the LID behavior was obtained by multiplying frequency 
intensity. A total daily severity score for each animal was computed by
adding the severity scores of the individual LID behaviors. A total weekly
LID score for each animal was computed by averaging the daily severity
score for Monday, Wednesday, and Friday ratings.
To assess levels of TH, every sixth coronal section was stained with
antisera against the enzyme to visualize DA cells (Soderstrom et al.,
2010). Midbrain sections were incubated with TH primary antibody (1:
4000; Millipore) for 24 h at RT, followed by 90 min in goat anti-mouse
biotinylated IgG (1:400; Millipore) and developed using 0.05% 3,3-
diaminobenzadine. To quantify the degree of nigral TH neuron
depletion, stereological probes were applied using a BX52 Olympus mi-
croscope equipped with Microbrightfield stereological software and a
Microfire CCD camera (Optronics) using the optical fractionator
method according to previously published methods (Madhavan et al.,
2012). Cells were counted under the 60 oil-immersion objective. TH
cells were counted in sections 480 m apart using a grid size of
195  85 m and counting frame size of 50  50 m. The Gundersen
method for calculating the coefficient of error was used to estimate the
accuracy of the optical fractionator results. The coefficients were gener-
ally 0.1. The total number of TH cells in the substantia nigra was
compared between genotypes.
To measure levels of TH after unilateral DA depletion in the dorsal
striatum, 30-m-thick coronal sections across the rostral caudal extent
of the striatum were immunostained with rabbit anti-TH (1:1000; Milli-
pore). TH Immunoreactivitywas quantified froma threshold-subtracted
binary image using imageJ software. TH measurement on the ipsilateral
side was normalized to the control contralateral side.
Biochemistry. To prepare striatal synaptosomes, striatal tissue was har-
vested on ice from Vglut3 fl/fl;ChatCre(G)/ and Vglut3 fl/fl (4–6 mice each)
and manually homogenized 10 strokes in homogenization buffer (320 mM
sucrose, 4 mM HEPES, pH 7.3)  complete protease inhibitors tablet
(Roche). Lysate was spun at 900 g for 10min at 4°C, the supernatant (S1)
transferred to a newMicrofuge tube, and then spun at 10,000 g for 15min
at 4°C. The resulting pellet (P2) was resuspended in homogenization buffer
andaBCAprotein concentrationassayperformed tonormalize total protein
content. Samples (45g of protein) were diluted in Laemmli sample buffer
containing5%-mercaptoethanoland loadedontoa12%bis-trispolyacryl-
amide gel containing 0.1% sodium dodecylsulfate. Gels were transferred to
PVDFmembranes and blocked in PBS 0.1%Tween 20 (PBST) 5%dry
milk for 1 h at RT. Blots were incubated with rabbit -VAChT antibody
1:1000 (Life Technologies) at 4°C overnight. After 3 10 min washes in
PBST buffer, blots were incubated with anti-rabbit horseradish peroxidase
secondary antibodies (Jackson ImmunoResearch) for 1 h at RT. Blots were
washed threemore times in PBST before the addition of Supersignal chemi-
luminescent substrate (Thermo Fisher Scientific) and imaging.
To analyze phospho-Ser40 TH levels, Western blot analysis was per-
formed as above except that the striatumwas dissected and then homog-
enized and spun at 20,000  g for 20 min at 4°C. The supernatant was
used to determine protein concentrations and the resulting blot was
probed using rabbit -phosphoS40-TH 1:1000 (Millipore).
Histology. To analyze spine density and dendritic arborization, mice
were euthanized and the brain immediately removed and stained with
the FD Rapid Golgi Stain Kit according to the manufacturer’s instruc-
tions (FD Neurotechnology). Briefly, brains were incubated in solutions
A and B (1:1) for 7 d in the dark at RT, changed to solution C for 4 d at
4°C, and then rapidly frozen in isopentane and stored at80°C. Golgi-
stained brains were then sectioned at 100 m thickness and dehydrated
with successive ethanol and xylene treatments. Slices were thenmounted
on slides and coverslipped with Permount (Sigma-Aldrich). Spines were
imaged by bright-fieldmicroscopy (Olympus IX71 invertedmicroscope)
with a 60 magnification oil objective (numerical aperture 1.65) and
Rolera-XR camera at coordinates 1.5 to 0.15 AP, 1.75 to 1.0 ML, and
2.5 to 3.5 DV for dorsal striatum and 1.5 to 1.0 AP, 1.0 to 1.5 ML,
and4.25 to4.75DV for ventral striatum. Two independent research-
ers blind to genotype manually counted the spines. Dendrite length was
measured using MetaMorph software (Olympus).
Electrophysiology. For whole-cell patch-clamp recording in striatal
slices, male and female mice (6–8 weeks of age) were euthanized either
before 11:00 A.M. (sleep cycle) or after 2:00 P.M. (waking cycle) and
300-M-thick coronal slices were cut using a vibrating microtome (Leica
Vibrotome 200C) with the tissue submerged in an ice-cold, sucrose-
based solution containing the following (in mM): 79 NaCl, 23 NaHCO3,
68 sucrose, 12 glucose, 1.1,NaH2PO4, 6MgCl2, and 0.5CaCl2. Sliceswere
then allowed to recover at RT for a minimum of 1 h in oxygenated
artificial CSF (ACSF) containing the following (inmM): 118NaCl, 3 KCl,
2.5CaCl2-2H2O, 1.5MgSO4, 0.6NaH2PO4, 25NaHCO3, and 10 glucose.
Whole-cell patch-clamp recordings were performed using borosilicate
pipettes (4–6 M resistance) filled with an internal solution containing
the following (inmM): 135 K-gluconate, 4 NaCl, 2MgCl2, 10 HEPES, 0.2
EGTA, 2.5 ATP-Na2, 0.2 GTP-Na, with or without 0.2% biocytin and
0.01% Alexa Dextran 488. Most recordings were performed without
compensation; however, several cells were recorded first without com-
pensation and then with whole-cell compensation and there was no dif-
ference in the results. Cells in which series resistance changed20%over
the course of the recording were excluded from analysis. MSNs were
identified by their size (10–15 m diameter), resting potential (Vr
between 70 and 90 mV), low input resistance (between 50 and 200
M), and regular (nonadapting) firing pattern in response to current
injection.
For FSCV, evoked DA release from coronal sections of the striatum
(300 m) was measured from male mice (8 to 24 weeks old) euthanized
either before 11:00 A.M. (sleep cycle) or after 6:00 P.M. (waking cycle).
Slices were allowed to recover for 1.5 h in oxygenated ASCF containing
the following (in mM): 125 NaCl, 2.5 KCl, 26 NaHCO3, 2.4 CaCl2, 1.3
MgSO4, 0.3 KH2PO4, 10 glucose) at RT, placed in a recording chamber,
and superfused (1 ml/min) with ACSF at 36°C. Electrochemical record-
ings and electrical stimulation were performed as described previously
(Zhang and Sulzer, 2003). Briefly, freshly cut carbon fiber electrodes5
m in diameter were inserted into the dorsal striatum or nucleus accum-
bens shell or core at a location of 50 m into the slice. For FSCV, a
triangular voltage wave (400 to900 mV at 280 V/s versus Ag/AgCl)
was applied to the electrode every 100 ms and current recorded using an
Axopatch 200B amplifier (Axon), with a low-pass Bessel filter set at 10
kHz, digitized at 25 kHz (ITC-18 board; Instrutech). Slices were electri-
cally stimulated every 2 min with either a single pulse, 2, pulses, 4 pulses,
or 10 pulses using a bipolar stimulating electrode 100 m from the
recording electrode. Background-subtracted cyclic voltammograms
identified the released substance as DA. The DA oxidation current was
converted to concentration based upon a calibration of 5MDA inACSF
after the experiment.
Statistics. Unless otherwise noted, data represent the mean
 SEM and
were analyzed by Prism version 5 software (GraphPad). Automated Scholl
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analysis was performed with a combination of ImageJ, NeuronJ, Bonfire
software, NeuronStudio, andMATLAB. The coefficient of error, a measure
of sampling error, was calculated for each animal and group for each stereo-
logical analysis. Unless otherwise stated, statistical analysis consisted of a
2-wayANOVAwithan	0.05andaBonferroniposthocanalysis.Asterisks
indicate statistical significance in the post hoc analysis as follows: *p 0.05,
**p 0.01, and ***p 0.001.
Results
To better characterize the hyperlocomotor activity of the global
VGLUT3 KO mice, we assessed ambulatory activity across the
circadian cycle in a home cage environment (Fig. 1A). Compared
withWT littermates, VGLUT3KOmice showed a robust increase
in total ambulations (peak of night 2; 237 
 35%) during the
waking cycle (nighttime), but no difference during the sleep cycle
(daytime) (2-way ANOVA, p	 0.0002). Because the motivating
factors that underlie locomotor behavior in a home cage may
differ from those engaged outside of the home cage, we alsomea-
sured ambulatory activity in the open field for 7 h spanning the
sleep–awake cycle (Fig. 1B). Locomotor activity after the day–
night transitionwas also significantly greater comparedwith con-
trols (81.9 
 10.6% Student’s t test, p 	 0.0083). Therefore,
VGLUT3 KO mice show robust hyperlocomotor activity only
during the waking state and this is not dependent on a home cage
environment.
Hyperlocomotor activity is often accompanied by increased
rearing behavior in rodents. However, the global VGLUT3 KO
mice did not show a change in rearing at night despite being
hyperactive (day 1: 58.7
 11% increase in total ambulations, p	
0.0073; day 2: 83.7
 13.7% increase, p	 0.0079; day 3: 67.2

29.2% increase, p 	 0.0214). Interestingly, compared with the
littermate control mice, KOs showed a decrease in rearing during
the daytime, which continued to decrease on consecutive days
(37.1 
 8.1% decrease on day 3; Student’s t test p 	 0.038; Fig.
1C). The data therefore indicate a mechanism present in the
VGLUT3 KO mice that suppresses ambulatory-related rearing.
Hyperlocomotor activity in mice is often causally linked to an
increase in striatal DA signaling (Gras et al., 2008; Bello et al.,
2011; Brown et al., 2011). We therefore measured evoked DA
release in striatal slices taken from VGLUT3 KO and WT litter-
mates at night and during the day using FSCV. Relative to control
littermates, VGLUT3 KOmice released significantly more DA in
response to single-pulse stimulation of the dorsal striatum when
measured at night (50 
 17%, p 	 0.0006; Fig. 1D). DA release
was also significantly elevated in the nucleus accumbens shell
(48 
 10%, p 	 0.0031) and core (45 
 16%, p 	 0.0115). In
contrast, no significant difference in DA release was detected in
the striatum measured during the day. Therefore, evoked DA
release in the KO corresponds to changes in locomotor activity.
The increased release of DAmay reflect an increase in vesicu-
lar content or an effect on the modulation of release at the DA
terminal. Because cytoplasmic DA levels are kept extremely low
through tight regulation, measurement of tissue content can be
used to assess vesicular DA levels. We therefore measured the
content of DA in striatal tissue by HPLC at night and during
the day. At night, DA levels were indeed significantly higher in
tissue from VGLUT3 KO mice compared with WT littermate
controls (16.8
 5.5%, p	 0.0005; Fig. 1E). Levels of the metab-
olites DOPAC and 3-MT did not differ and levels of norepineph-
rine, epinephrine, 5-HT, and the 5-HT metabolites 5-HIAA and
HVA were also unchanged. As expected, there was no significant
difference in DA levels fromwhole striatal tissue collected during
the daytime (Fig. 1E). Because increased vesicular DA content
can result from an increase inDA synthesis, wemeasured levels of
the active form of the rate-limiting enzyme for synthesis, phos-
phorylated tyrosine hydroyxlase (pTH) using Western blot.
When tissue was harvested at night, pTH levels were significantly
increased compared with littermate controls (92.8 
 24.3%,
2-way ANOVA, p	 0.001; Fig. 1F). No significant difference in
pTH levels were detected between genotypes when whole striatal
tissue was collected during the day. Together, the data indicate
that loss of VGLUT3 leads to an increase in striatal DA synthesis,
packaging, and release that depends on the circadian cycle, point-
ing to a previously unappreciated role for the transporter in reg-
ulating striatal DA transmission.
Properties of MSNs in the VGLUT3 KO mouse
Midbrain DA terminals form symmetric synapses on the den-
dritic spines and shafts of MSNs, where they modulate corticos-
triatal and thalamostriatal glutamatergic signaling and plasticity,
including MSN spine density (Centonze et al., 2001; Cazorla et
al., 2012; Fasano et al., 2013; Ishikawa et al., 2013). When har-
vested at night, spine densities in the dorsal and ventral striatum
were significantly increased in VGLUT3 KO animals (dorsal
striatum, 48.2
 1.5%, p	 0.001; ventral striatum, 41.1
 3.8%,
p 	 0.0019, Student’s t test; Fig. 2A). In contrast, MSN spine
densities measured during the day did not differ between geno-
types. To assess whether there were additional changes in the
structure of MSN dendrites, we performed Scholl analysis on the
slices harvested at night. We observed no difference in the num-
ber of Scholl intersections, branch points, or termination points
counted in either the dorsal or ventral striatum (Fig. 2B). Last, we
investigated whether the transient increase in spines at night gen-
erated new functional contacts by performing whole-cell patch-
clamp recordings in the dorsal striatum of KO and WT
littermates. No differences were detected in the resting potential,
input resistance, firing rate or action potential properties (Fig.
2C,D). We also did not detect differences in MSN properties
between the two genotypes when cells were recorded during the
day (data not shown). Measures of spontaneous activity can in-
dicate altered connectivity, but no change in this parameter was
observed across the circadian cycle (Fig. 2E). Therefore, MSN
spine density in VGLUT3 KO mice is highly dynamic across the
circadian cycle and correlates with changes in the level of DA
release. Consistent with their transient nature, electrophysiolog-
ical measurements indicate that the additional spines observed at
night in the KO are functionally immature.
Cholinergic-neuron-specific deletion of VGLUT3
Striatal cholinergic interneurons have a profound influence on
the striatal microcircuitry, including the regulation of DA signal-
ing, and can potentially act through the release of ACh or gluta-
mate. A previous report demonstrated that abolishing only ACh
release fromCINs through the selective deletion of VAChT in the
striatumdoes not affect locomotor activity (Guzman et al., 2011).
To determine whether glutamate signaling by CINs has a role, we
used our newly generated Cre-lox conditional KO mice
(Vglut3 fl/fl; Fig. 3A; Peirs et al., 2015). As a control, we also deleted
VGLUT3 globally in this line by crossing theVglut3 fl/fl mice to the
germline deleter strain Rosa26-Cre and refer to these mice as
Vglut3 / (Fig. 3A–E). Western blot analyses of brain tissue
showed normal levels of the transporter inVglut3 fl/fl mice and an
absence of VGLUT3 in the germline-deleted mice (Peirs et al.,
2015). Immunohistochemical analysis from the Vglut3 / mice
also showed a complete loss of the transporter in brain (Fig. 3C)
and peripheral neurons known to express it (Peirs et al., 2015).
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Figure 1. VGLUT3 KOmice display circadian-dependent hyperdopaminergia. A, Ambulatory activity of VGLUT3 KO (red) andWT littermates (black) in a home cage environment (n	 8
mice per condition). Dark regions indicate the nighttime/awake cycle. B, Locomotor activity in open field for VGLUT3 KO (red) and WT (black) mice (n	 6 mice per genotype). Total
ambulations measured across the sleep/wake cycle (dark region of graph indicates the awake cycle). Total ambulations during the awake cycle (insert). Data were analyzed by Student’s
t test. C, Rearing behavior of VGLUT3 KO (day: red; night: green) and WT littermates (day: black; night: gray) in an open field (left). Ambulatory behavior of VGLUT3 KO (day: red; night:
green) and WT littermates (day: black; night: gray) measured in conjunction with rearing behavior (right). Data were normalized to WT activity and analyzed by Student’s t test (n	 9
mice and 6 mice for the day and night, respectively). D, FSCV of evoked DA release in dorsal striatum, nucleus accumbens (nAcc) core and shell. Representative traces of DA release from
WT (closed circles) and VGLUT3 KO littermates (open circles) in the nAcc core and dorsal striatum (top); average concentration of DA released in VGLUT3 KO (red) andWT (black) littermates
(n	 9 male mice per genotype; bottom). E, HPLC of biogenic amines (pmol/mg tissue) in VGLUT3 KO (red) andWT (black) littermates (top); ratio of DOPAC and DA (insert; n	 12 female
and 7 male mice for KOs and 9 female and 7 male mice for WTs). HPLC of striatum harvested during the day (bottom; n	 5 mice per genotype). F, Ratio of striatal pTH to NeuN in VGLUT3
KO (red) andWT littermates (black; n	 4 female and 2 male mice per group) in a Western blot analysis (left). VGLUT3 immunoreactivity in striatal tissue harvested during the sleep cycle
(DAY) and waking cycle (NIGHT; right). A pTH band appears at62 kDa and the control marker NeuN appears at48 kDa. ( A–F) Data are displayed as the mean
 SEM and unless
otherwise noted were analyzed by 2-way ANOVA genotype day with a Bonferroni post hoc test. n.s., Not significant; *p 0.05, **p 0.01, ***p 0.001.
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Finally, consistent with the original global deletion, VGLUT3/
mice do not startle to a loud sound (Fig. 3E; Seal et al., 2008).
Previous data suggest that cholinergic forebrain neurons, but
not cholinergic cortical interneurons or hindbrain neurons, ex-
press VGLUT3 (Gritti et al., 2006; Nickerson et al., 2006; Wang
and Morales, 2009). To confirm this expression pattern, we
crossed our BAC transgenic Vglut3Cre/ mice (Grimes et al.,
2011) to the lsl-tdTomato reporter line (Madisen et al., 2010) and
then costained brain sliceswith an antibody to the cholinergic cell
marker ChAT. In this mouse line, tomato expression reflects all
cells that have ever expressed Cre (VGLUT3). We observed colo-
calization of the tomato and ChAT in striatal cholinergic in-
terneurons, as well as cranial nerves III, IV, andVI and a subset of
basal forebrain cholinergic neurons (Fig. 4C–F), but the tomato
reporter was not observed in hindbrain cholinergic nuclei (LDT
and PPTg; Fig. 4,A,B, respectively) or in cortical cholinergic
interneurons.
To delete VGLUT3 from cholinergic interneurons, we crossed
the Vglut3 fl/fl line to mice that express Cre under the control of
Chat gene regulatory elements [Chat-Cre(G)mice]. As expected,
VGLUT3 immunoreactivity was not detected in striatal cholin-
ergic interneurons of Vglut3 fl/fl;ChatCre(G)/ mice (Fig. 5A). To
determine whether loss of VGLUT3 from cholinergic neurons is
sufficient to produce the hyperlocomotor behavior, wemeasured
ambulatory activity continuously for 48 h (Fig. 5B). Contrary to
the prevailing hypothesis, Vglut3 fl/fl;ChatCre(G)/ mice showed
normal levels of locomotor activity across the circadian cycle.
Because the gene locus of Chat also encodes the gene for Vacht,
the use of this BAC transgenic line may have introduced in-
creased copies of the Vacht allele, as has been observed in other
Figure2. Morphological and electrophysiological properties ofMSNs.A, Average spine density ofMSNs located in the dorsal striatum fromVGLUT3KO (blue) orWT (green) littermates during the
day (top left) and night (topmiddle). Average spine density ofMSNs in ventral striatum of KO (blue) orWT (green) littermates during the day and night (bottom left, bottom-middle). Spine density
of each cell measured in the KO (red) andWT (black) animals. Black bars indicate themean and colored bars indicate the SEM for all animals of a particular condition (left; 12–17 cells and n	 3–4
malemice per condition). Representative Golgi-stained images fromKO andWT littermates for each condition are shown (top right, bottom right).B, Scholl analysis ofMSNs fromdorsal and ventral
striatum from the same animals used in A. Number of dendritic intersections with Scholl rings fromMSNs located in the dorsal striatum are shown at top left. Number of branch points and terminal
points fromdorsalMSNs are shownat bottom left. Scholl intersections fromventral striatumMSNsare shownat top right. Number of branchand terminal points in ventralMSNs are shownat bottom
right. C, Representative voltage responses to current injections in VGLUT3 KO mice (red; left) and WT littermates (black; right). D, MSN electrophysiological properties from KO andWT littermates
recorded during the nighttime (n	 14- 18 cells from 4 female and 1 male mice for each condition). E, Spontaneous EPSC amplitudes from MSNs during the daytime and nighttime (left) and
frequency of EPSCs from both times of day (right; n	 9- 11 cells from 5 female and 1 male mice per condition). Data are presented as the mean
 SEM and were analyzed by 2-way ANOVA
genotype day with a Bonferroni post hoc test (A, B) or a Student’s t test (D, E). N.S., Not significant.
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BAC transgenic lines constructed using
this locus (Nagy and Aubert, 2012; Kolis-
nyk et al., 2013; Crittenden et al., 2014). In
this case, elevated levels of VAChT may
have raised vesicular ACh content and
thus suppressed the normally elevated lo-
comotor activity of the KO during the
waking cycle. To determine whether
VAChT expression is increased in the
BAC transgenic line, we performedWest-
ern blot analysis of striatal synaptosomes
taken from ChatCre(G)/ and WT litter-
mates. VAChT levels in the ChatCre(G)/
mice were2-fold higher (90
 32% in-
crease, Student’s t test, p	 0.022; Fig. 5C),
similar to other BAC transgenic lines con-
structed using the Chat locus. To deter-
mine whether this increased VAChT
expression masked the hyperlocomotor
activity of global VGLUT3 KO mice, we
generated Vglut3 /ChatCre(G)/ mice.
Thesemice demonstrated robust hyperlo-
comotor activity that did not differ statis-
tically from the global KO alone (Fig. 5D),
thus indicating that the 2-fold higher ex-
pression of VAChT did not suppress the
hyperlocomotor activity.
To avoid the potential for confounds
introduced by the ChAT-Cre(G) line, we
used the knock-in ChAT-IRES-Cre line in
all future experiments. In these mice, Cre
was knocked into the 3UTR of the Chat
locus, avoiding effects on ChAT or
VAChT levels (Rossi et al., 2011). Immu-
nohistochemical analysis of striatal slices
from Vglut3 fl/fl;Chat IRESCre/ mice con-
firmed deletion of VGLUT3 in CINs
(Fig. 6A). Tested over 48 h, Vglut3 fl/fl;
Chat IRESCre/ mice also showed normal
ambulatory activity over the entire circa-
dian cycle (Fig. 6B), again indicating that
loss of VGLUT3 in cholinergic neurons
does not affect locomotor activity.
The relationship between CIN-
mediated signaling and evokedDA release
is complex (Zhou et al., 2002; Cachope et
al., 2012) and may include a role for CINs
in gating the frequency dependence of
DA release (Zhang and Sulzer, 2004;
Threlfell et al., 2012). We therefore also
measured evoked DA release in the dorsal striatum of
Vglut3 fl/fl;Chat IRESCre/mice using FSCV. DA release evoked by
a single pulse stimulation was similar between Vglut3 fl/fl;
Chat IRESCre/ and littermate controls, suggesting that DA release
from the readily releasable pool of vesicles is not altered by the
loss of VGLUT3 (Fig. 6C, left). To determine whether DA re-
leased from the total pool of vesicles was altered, we applied 70
mM KCl to the slice (Gubernator et al., 2009; Rodriguez et al.,
2013). We also did not detect a difference in DA release under
these conditions (Fig. 6C, right). Finally, wemeasured the level of
DA release evoked by trains of either 4 or 10 pulse stimulations
performed at either 20 or 100 Hz. DA release was again similar
between genotypes under these conditions (Fig. 6D). Therefore,
loss of VGLUT3 from CINs does not alter evoked DA release in
the dorsal striatum. Consistent withmeasurements of locomotor
activity and DA release, HPLC analysis of whole striatal DA con-
tent measured in mice that were euthanized at night was also
similar between genotypes (Fig. 6E). Finally, in agreement with
the lack of enhanced DA release, MSN spine densities mea-
sured in both dorsal striatum and ventral striatum of
Vglut3 fl/fl;Chat IRESCre/ mice were similar to Vglut3 fl/fl mice
when the animals were euthanized at night (Fig. 6F ).
To determine whether the altered rearing behavior observed
in the Vglut3 /mice was due to a loss of VGLUT3 specifically
from cholinergic neurons, we measured rearing in the
Vglut3 fl/fl;Chat IRESCre/ and littermate mice across 3 d (Fig. 6G).
Figure 3. Generation and characterization of VGLUT3 conditional KO line. A, Construction of the BAC vector. The FRT flanked
TK-neo gene was deleted by crossing founders to the Rosa26 Flp. Exposure to Cre recombinase excises exon 2. B, Southern blot
analysis of ES cell clones showproper targeting of the left and right arms in clones 2 and 3. C, IHC ofVglut3 /mice depicting loss
of VGLUT3 expression fromnuclei known to express the transporter. 10 images taken from striatal slice stained for VGLUT3 (left;
488 nm) and ChAT (right; 594 nm; top); 10 images taken of the hippocampus stained for VGLUT3 (left; 488 nm) and GAD65/67
(right; 594nm; bottom). Scale bar, 50mfor all images.D, PCR-basedgenotyping using primers 1 and2 to detect the floxed allele
andprimers 2 and3 to detect the recombined allele.E, Acoustic startle is robust inVglut3 fl/fl (black) and absent inVglut3 /mice
(red). Data are the mean
 SEM for n	 2 female and 4 male mice per genotype.
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Compared with the littermate control mice, rearing episodes
were significantly attenuated on the third day (42.0 
 8.7% de-
crease, 2-way ANOVA, p	 0.0116). Therefore, although loss of
VGLUT3 from cholinergic neurons does not produce hyperloco-
motor behavior, it does influence rearing behavior.
The dorsal striatum is important for the processing of senso-
rimotor information and alterations in circuitry can influence
behaviors such as the ability of a brief noise, or prepulse, to in-
hibit acoustic-induced startle responses. Ablation of CINs was
shown to reduce the prepulse inhibition of startle (PPI; Laplante
et al., 2011), but the deletion of VAChT in the striatum does not
alter PPI (Guzman et al., 2011), thus pointing to a potential role
for CIN-mediated glutamate signaling in regulating this behav-
ior. We therefore used the Vglut3 fl/fl;Chat IRESCre/ mice to test
whether PPI is altered by the loss of VGLUT3-mediated gluta-
mate signaling. Compared with WT littermates, Vglut3 fl/fl;
Figure 4. Expression of VGLUT3 in cholinergic nuclei. Shown are 10 images (A–C) and 20 images (D–F ) from lsl-tdTomato;VGLUT3 Cre mice costained for ChAT (blue) reveals overlap of
cholinergic and Tomato (VGLUT3) populations.A, Laterodorsal tegmental nucleus (LDTg).B, Pedunculopontine tegmental nucleus (PPTg). C, Medial septum (Med. Sept.) and lateral septum (Lat.
Sept.).D, Oculomotornerve (OcM/III) andaqueduct (Aq).E, Abducensnerve (Aduc.N/VI) and fourth ventricle (4V).F, Trochlearnerve (Troch.N/IV). Scalebar, 50mfor10and20 images (left three
images). Scale bar, 12m for high-magnification images (right).
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Chat IRESCre/mice showed significantly larger startle amplitudes
after the prepulse (slope Vglut3 fl/fl;Chat IRESCre/ 	 2.25
 0.39,
slope WT 	 3.31 
 0.36; linear regression analysis, p 	 0.0477;
Fig. 7A), indicating impaired PPI. Baseline acoustic startle ampli-
tudes were not different between the two genotypes. We also
tested the Vglut3 fl/fl;ChatCre(G)/, which have increased levels of
VAChT and potentially more ACh release. Interestingly, PPI in
these mice was not significantly different from in the controls
(Fig. 7B), suggesting that CIN-mediated signaling carried by ei-
ther glutamate or ACh is sufficient to maintain normal PPI.
Loss of VGLUT3 ameliorates motor symptoms in a
Parkinson’s disease model
Parkinson’s disease is a progressive neurodegenerative disorder
that results in large part from a dramatic loss of nigrostriatal DA
neurons and can bemodeled inmice by the chemical lesioning of
striatal DA terminals with the toxin 6-OHDA (Evetts et al., 1970;
Ng et al., 1971; Steece-Collier et al., 2002; Grealish et al., 2008).
We hypothesized that the increased striatal DA release in
VGLUT3 KOmice would compensate for the reduced nigrostri-
atal DA in a model of Parkinson’s disease, thereby improving
motor function. Unilateral DA depletion was achieved by inject-
ing 6 g of 6-OHDA into the dorsomedial striatum and motor
behavior monitored 1–3 weeks later. To determine the extent of
DA lesioning, TH immunoreactivity was quantified every 300
m across the dorsal striatum in the rostral–caudal direction
(Fig. 8A). The percentage decrease in ipsilateral TH immunore-
activity (compared with contralateral) did not differ between ge-
notypes (67.4
 8.0% for KO and 74.9
 6.3% forWT; Student’s
t test, p 	 0.49). We additionally analyzed DA levels by HPLC
using a 1.6-mm-diameter tissue punch taken from the dorsome-
dial striatum. Again, no difference was observed between KO and
WT littermates (98.4 
 0.3% reduction for KO mice, 99.6 

0.1% reduction for WT mice).
To assess motor function, we measured spontaneous rota-
tions in the open field and front paw contacts made during rear-
ing in a cylinder (Fig. 8B). Spontaneous rotations toward the
injected or ipsilateral (left) side are enhanced by unilateral deple-
tion of nigrostriatal DA (Von Voigtlander and Moore, 1973).
Before injection of 6-OHDA, the number of CW (right) and
CCW (left) rotations made over a 15 min period was the same in
VGLUT3 KO and WT littermates at night and during the day.
After unilateral DA depletion, the WTmice showed a significant
increase in spontaneous rotations to the ipsilateral (CCW; left)
side when measured during the day (78.5 
 4.1%, 2-way
ANOVA, p	 0.0002) and a significant increase at night (70.4

7.4%, p 	 0.0087; Fig. 8B, top). Remarkably, with the same de-
gree of DA depletion, turning behavior in the VGLUT3 KO was
completely unaffected across the circadian cycle.
Paw preference in the cylinder assay is also sensitive to unilat-
eral DA depletion, showing a dramatic bias toward reaching with
the ipsilateral paw (Glajch et al., 2012). Before injection of
6-OHDA, VGLUT3 KO and WT littermates showed equal con-
tralateral and ipsilateral, weight-bearing paw contacts during
rearing (Fig. 8A, bottom). After injection, the WT mice demon-
strated a significant increase in ipsilateral paw reaching both dur-
ing the day (70
 7%, 2-way ANOVA, p	 0.0008) and at night
(69 
 7%, p 	 0.0007). In contrast, VGLUT3 KO mice showed
no paw preference at either time of day (day: ipsilateral: 54.9 

1.8%; contralateral: 45.1 
 1.8%; p 	 0.19; night: ipsilateral:
53.6
 2.4%; contralateral: 46.5
 2.3%; p	 0.29). In summary,
our experiment showed that, despite undergoing a similar degree
of DA depletion after 6-OHDA treatment, VGLUT3 KO mice
Figure 5. KO of VGLUT3 in cholinergic neurons using the Chat Cre( G) mouse line. A, Epifluorescent images of brain slices from Vglut3 fl/fl;Chat Cre(G )/mice. 10magnification of the striatum
immunostained for VGLUT3 (488 nm; left) and ChAT (594 nm; left-middle). Scale bar, 50 m. A 40 image of the cortex immunostained for VGLUT3 is shown (right). Scale bar, 20 m. B,
Ambulatory activity of Vglut3 fl/fl;Chat Cre( G)/ and Vglut3 fl/fl littermates (n	 14 male and 11 female mice per genotype). Dark regions indicate the awake cycle. C, Western blot of striatal lysates
from Vglut3 fl/fl;Chat Cre(G)/ and Vglut3 fl/fl littermates probed for VAChT. Relative levels of VAChT in Vglut3 fl/fl;Chat Cre(G )/mice (blue) compared with Vglut3 fl/fl (black) controls (left). Immuno-
reactivity to VAChT appears at57 kDa (top right); loading control synaptophysin at37 kDa (bottom right). Data are presented as the mean
 SEM (n	 8 mice per genotype) normalized to
loading controls and were analyzed by Student’s t test. D, Ambulatory activity of Vglut3 /;Chat Cre(G )/mice (n	 4 female and 8male mice) and VGLUT3/ littermates (n	 4 female and 6
male mice). Dark regions indicate the waking cycle and the dotted line indicates the mean activity of Vglut3 fl/fl;Chat Cre(G )/mice taken from B. Data are presented as the mean
 SEM and were
analyzed by 2-way ANOVA genotype day with a Bonferroni post hoc test (B, D). *p 0.05.
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Figure6. Locomotor activity and striatal DA signaling in the Vglut3 fl/fl;Chat IRESCre/mouse. A, IHC images taken at 10magnification of the striatum and surrounding cortical regions
in Vglut3 fl/fl;Chat IRESCre/ (top) and Vglut3 fl/fl (bottom) mice stained for VGLUT3 (left) and VAChT (right). Scale bars, 50m. B, Ambulatory activity of Vglut3 fl/fl;Chat IRESCre/ (blue)
mice and Vglut3 fl/fl (black) littermates (n 	 14 and 12 mice, respectively). Dark regions indicate the waking cycle. C, FSCV of evoked DA release measured in dorsal striatum of
Vglut3 fl/fl;Chat IRESCre/ (blue) and Vglut3 fl/fl (black) mice (n	 5 male mice per genotype). Single pulse stimulation is shown at left; KCl stimulation on the right. Data were analyzed by
Student’s t test.D, DA release from 2, 4, and 10 stimulation pulses was normalized to release from a single pulse. Stimulation pulses at 20 Hz (left) and 100 Hz frequency (right; n	 11–23
cells and 5 male mice per genotype). E, HPLC for biogenic amines (pmol/mg tissue) from striatum of Vglut3 fl/fl;Chat IRESCre/ (blue) and Vglut3 fl/fl (black) littermates; ratio of DOPAC and
DA (insert; n	 10 mice per genotype). F, Average spine density of individual MSNs (Vglut3 fl/fl;Chat IRESCre/: blue; Vglut3 fl/fl: black) located in the dorsal striatum (left) and ventral
striatum (right) of Vglut3 fl/fl;Chat IRESCre/ (gray) and Vglut3 fl/fl (green) mice. Data were analyzed by Student’s t test (12–13 cells from n	 3 mice per genotype). G, Rearing behavior
of Vglut3 fl/fl;Chat IRESCre/ (blue) and Vglut3 fl/fl (black) littermates in the open field (n	 15 mice per group; left). Ambulatory activity for Vglut3 fl/fl;Chat IRESCre/ (blue) and Vglut3 fl/fl
(black) littermates in an open field (n	 14 and 12 mice per genotype; right). B–G, Data are presented mean
 SEM and were analyzed by 2-way ANOVA genotype time with a
Bonferroni post hoc test. n.s., Not significant; *p 0.05.
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exhibited normal motor behavior in contrast to the WT control
mice, which showed the typical motor deficits.
Because anti-cholinergics have been shown to have therapeu-
tic value for Parkinson’s disease, we investigatedwhether deletion
of VGLUT3 from cholinergic neurons contributes to the im-
provedmotor function after unilateral striatal DAdepletion.One
week after injection of 6-OHDA, rotational behavior was mea-
sured in the Vglut3 fl/fl;Chat IRESCre/ mice and Vglut3 fl/fl litter-
mates (Fig. 8C, left). Both genotypes showed a significant
increase in spontaneous ipsilateral rotations in the open field
compared with before lesioning (CCW turning 71.7 
 13.3%,
2-way ANOVA, p 	 0.045; and 73.7 
 8.9%, p 	 0.0243 for
Vglut3 fl/fl;Chat IRESCre/ and Vglut3 fl/fl littermates, respectively).
Likewise, weight-bearing paw contacts in a cylinder were signifi-
cantly biased toward the ipsilateral paw in both sets of mice
(76.0
 10.1%, 2-way ANOVA, p	 0.001, and 68.0
 5.1%, p	
0.0059, for Vglut3 fl/fl;Chat IRESCre/ and Vglut3 fl/fl littermates, re-
spectively; Fig. 8C, right). Therefore, deletion of VGLUT3 in
CINs does not ameliorate themotor deficits caused by DA deple-
tion. The improved motor function of the global VGLUT3 KO
mice is likely due to the upregulation of themidbrain DA system,
which does not occur in the conditional KO.
Global loss of VGLUT3 prevents L-dopa-induced dyskinesias
L-dopa is the principal treatment strategy for Parkinson’s disease.
Administration of the precursor for DA synthesis alleviates mo-
tor dysfunction by restoring levels of the monoamine. However,
long-term administration of the drug often results in hyperki-
netic, involuntary movements known as LIDs. Mechanisms un-
derlying this basal-ganglia-dependent behavior are unknown. To
determine whether VGLUT3 has a role in the development of
LID, we assessed dyskinetic behavior in VGLUT3 KO and WT
littermates. We first lesioned the median forebrain bundle with
6-OHDA and then administered daily injections of 1, 2, or 3
mg/kg L-dopa (see timeline in Fig. 9A). The extent of lesioning
was determined by counting the total number of THneurons in
the substantia nigra pars compacta using the optical fractionator
(StereoInvestigator; MBF Bioscience). No difference was ob-
served between the VGLUT3 KOs (93.3 
 1.5%; percent TH
neuron loss compared with intact side) and their WT littermates
(96.0 
 1.5%). Daily administration of low dose (1 mg/kg)
L-dopa for 1 week resulted in the emergence of low-level LID
behavior in both genotypes (Fig. 9B). In the second week of drug
treatment, L-dopa was administered daily at a higher dose (2
mg/kg) and, at this dose, a significant difference in severity of LID
between genotypes began to emerge. Mean LID severity scores
were significantly less in KO mice than WTs at peak dose 20 and
40 min after injection. In the third and fourth weeks of drug
treatment, the daily dose of L-dopa was further increased to 3
mg/kg with or without a 2-week drug-free washout period, re-
spectively. The severity of LID continued to be significantly at-
tenuated in the VGLUT3 KOs compared with WT controls at 20
and 40 min after injection of L-dopa (Fig. 9B). The difference in
LID severity between the genotypes was maintained when data
were analyzed for median and maximum LID score across dose
and time (Fig. 9C,D, respectively; median LID score: F(1,15) 	
18.03, p 	 0.0001; maximum LID score: F(1,15) 	 7.383,
p 	 0.016) Therefore, in addition to ameliorating the motor
symptoms of nigrostriatal DA depletion, loss of VGLUT3 also
markedly attenuates the development of LIDs.
The ablation of cholinergic interneurons has also been dem-
onstrated to ameliorate the severity of LID behaviors (Won et al.,
2014). To assess whether loss of the glutamate release mediated
by CINs is sufficient to attenuate LID, we repeated the experi-
ment with the Vglut3 fl/fl;Chat IRESCre/ mice (Fig. 9E). Although
not statistically significant, we did observe a strong trend of the
Vglut3 fl/fl;Chat IRESCre/mice to show less LID than their control
littermates, indicating there may be some contribution from the
loss of VGLUT3 in CINs.
Discussion
Our present work shows that VGLUT3 regulates the basal gan-
glia, including the striatum, through multiple mechanisms. The
global KO mice are significantly hyperlocomotive during their
waking cycle and show a concomitant increase in the synthesis,
packaging, and release of DA in both the ventral and dorsal stria-
tum (Table 1). The increase in locomotor activity is consistent
with increased DA synthesis and release, but the basis for the
circadian dependence of the phenotype is less clear. Locomotor
activity and extracellular DA levels normally fluctuate in a
circadian-dependent manner, with higher extracellular levels of
the transmitter occurring in the striatumduring thewaking cycle.
However, the mechanism does not depend on the synthesis of
additional DA, but rather on changes in the clearance rate set by
the abundance of DA transporter on the plasmamembrane (Fer-
ris et al., 2014).
Mouse mutants that show a circadian-dependent change in
locomotor activity typically involve genes that regulate the circa-
dian cycle directly, such as Per1, Per2, Clock, and NR1D1 (Mc-
Clung 2013). Indeed, studies have begun to focus on the
relationship between circadian regulation of the midbrain DA
system and mood disorders such as mania or attention deficit-
hyperactivity disorder (ADHD). For example, a mutation of the
Clock gene (Clock19) in mice produces circadian-dependent
hyperlocomotion resembling mania that correlates with in-
creased DA neuron activity and pTH levels (McClung et al.,
Figure 7. Prepulse inhibition. A, Acoustic startle response to increasing noise intensity in
Vglut3 fl/fl;Chat IRESCre/ (blue) andVglut3 fl/fl (black) littermates (n	4 female and2malemice
per genotype). Startle response to sounds from 75 to 115 dB SPL (500 ms each; left). Startle
response to 115 dB SPL noise exposures after a brief prepulse noise exposure ranging from65 to
85 dB SPL (right). B, Same as in A except with Vglut3 fl/fl;Chat Cre(G)/ (blue) and Vglut3 fl/fl
(black) littermates. Data are the mean
 SEM and were analyzed by linear regression analysis
comparing slopes between genotypes. n.s., Not significant.
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Figure8. Analysis ofmotor function in DA-depleted VGLUT3 KOmice.A, Representative TH immunoreactivity across the striatum inWT (top) and KO (bottom)mice (left). Imageswere converted
to binary data after subtraction of background. Total percentage of TH loss in the ipsilateral side of the dorsal striatum comparedwith contralateral controls from a subset of KO (red) andWT (black)
mice used in (B; n	 3 KO and 4WTmice; right). Data are presented as the mean
 SEM and were analyzed by Student’s t test. B, Spontaneous rotations in either the CW or CCW direction in the
open field forVGLUT3KO (red) andWT (black)mice (n	11micepergenotype; top). Rotationsprelesionduring the sleep cycle (left); rotationspostlesionduring the sleep cycle (center left); rotations
prelesion during the awake cycle (center right); rotations postlesion during the awake cycle (right). Data were analyzed by 2-way ANOVA genotype day with a Bonferroni post hoc test.
Weight-bearingpawcontactswhile rearing in a cylinder for VGLUT3KO (red) andWT (black)mice (n	10and11mice for KOandWT, respectively; bottom). Contacts prelesionduring the sleep cycle
(left); contacts postlesion during the sleep cycle (center left); contacts prelesion during the awake cycle (center right); contacts postlesion during the awake cycle (right). C, Spontaneous rotations
in either the CWor CCWdirectionduring a 15min session in the open field forVglut3 fl/fl;Chat IRESCre/ (blue)mice andVglut3 fl/fl (black) littermates (left).Weight-bearingpawcontactswhile rearing
for Vglut3 fl/fl;Chat IRESCre/ (blue) mice and Vglut3 fl/fl (black) littermates (n	 5 and 6 for cKO and controls, respectively; right). B, C, Data are presented as themean
 SEM andwere analyzed by
2-way ANOVA genotype time with a Bonferroni post hoc test. n.s., Not significant; *p 0.05, **p 0.01, ***p 0.001.
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2005). In this mutant, the defect appears to originate within the
DA neurons themselves. Per1 KO mice demonstrate decreased
DA levels and display an ADHD-like phenotype (Huang et al.,
2015). Zebrafish mutants of Per1b show behaviors similar to the
Per1KOmice. Consistent with the behaviors, Per1bwas shown to
regulate the DA-related genes,monoamine oxidase and DA  hy-
droxylase, as well as DA neuron development (Huang et al.,
2015).
Only a few mouse mutants, like the VGLUT3 KO, exhibit a
circadian-dependent locomotor phenotype without an overt re-
lationship to altered circadian gene expression. For example,
mice lacking the orphan G-protein-coupled receptor GPR88
show nocturnal hyperlocomotor activity due to deletion of the
receptor in striatal output neurons, which produces an increase
in the excitability of the neurons (Quintana et al., 2012). In this
case, the increase inMSN activity appears to be sufficient to elicit
the hyperactivity, but the basis for the circadian dependence is
still not clear. One possibility is that controls on the locomotor
circuit are simply less restrictive during the waking cycle, with
fewer regulatory mechanisms in place to suppress activity, as op-
Figure9. L-dopa-induceddyskinesias inVGLUT3KOandWT littermates.A, Time course of experimental design.B, LID scores for VGLUT3KO (red) andWT (black) littermates.MeanLID scores after
injection of 1 mg/kg L-dopa (top left); 2 mg/kg L-dopa (top right); 3 mg/kg L-dopa (bottom left); or 2 weeks after initial 3 mg/kg data collection (n	 4 female and 2 males and n	 1 female and
3males for KO andWTs, respectively; bottom right). Datawere analyzed by 2-wayANOVAgenotype timewith a Bonferroni post hoc test. C,Median LID scores for each dose of L-dopa (1–3mg/kg)
across the 80 min testing period. D, Maximum LID scores observed for each dose of L-dopa (1 to 3 mg/kg) across the 80 min testing period. E, LID scores for Vglut3 fl/fl;Chat IRESCre/ (blue) and
Vglut3 fl/fl (black) littermates (n	 7 and 5 for cKO and control littermates, respectively). Mean LID scores from 3 d of testing every 20min (80min total) after injection of 1mg/kg L-dopa (top left);
2 mg/kg L-dopa (top right); 3 mg/kg L-dopa (bottom left); or 2 weeks after initial 3 mg/kg data collection (bottom right). B, E, Data are presented as themean
 SEM andwere analyzed by 2-way
ANOVA genotype time with a Bonferroni post hoc test. n.s., Not significant; *p 0.05.
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posed to the sleep cycle, where the maintenance of a low activity
state is desired. In the case of VGLUT3, our data suggest that the
transporter normally acts to suppress DA levels and locomotor
activity. This regulatory mechanism could itself be circadian in
nature or it may be constant but constrained by additionalmech-
anisms during the sleep cycle. Another factor that could influence
the observed phenotypes is the sex of the animals. However,
we observed no difference between male and female mice in the
upregulation of the DA system, such as hyperlocomotion, or in
the preservation of motor function after DA depletion. Future
work to identify the cell population(s) responsible for the hyper-
dopaminergic phenotypes could provide insight into its apparent
circadian dependence.
The normal locomotor activity and DA release in the dorsal
striatumofmice lacking VGLUT3 specifically in cholinergic neu-
rons was somewhat surprising given previous results showing
that loss of VGLUT3 from CINs decreases cholinergic signaling
(Gras et al., 2008; Nelson et al., 2014). Classic theories positioned
DA and ACh as antagonists of one another and DA does inhibit
CIN firing through activation of D2 receptors (DeBoer et al.,
1996). However, recent studies suggest that ACh enhances DA
release by activating nicotinic receptors on DA terminals (Exley
et al., 2008; Exley et al., 2012; Threlfell et al., 2012). Therefore,
decreasing ACh release, which occurs when VGLUT3 is deleted
from CINs (Gras et al., 2008; Nelson et al., 2014), would be ex-
pected to attenuate DA release, perhaps resulting in hypoloco-
motor behavior. This prediction is based on in vitro recordings,
whereas the in vivo circuitry is likely more complicated, thus
raising the possibility of other behavior outcomes. Indeed, Guz-
man et al. (2011) reported no change in locomotor activity when
VAChTwas deleted specifically fromCINs and suggested that the
CIN-mediated glutamate release might be important instead.
Our data now show definitively that the hyperlocomotor pheno-
type of the VGLUT3 KOmice has its origins in a noncholinergic
neuron population(s) and that abolishing glutamate release and
attenuating ACh release by CINs (and possibly basal forebrain
cholinergic neurons) does not alter baseline locomotor activity.
The deletion of VGLUT3 specifically in cholinergic neurons
does, however, alter two other behaviors: the prepulse inhibition
of startle and habituation to a novel environment with repeated
exposures. Disruption of PPI is often is a symptom of a schizo-
phrenic state and decreased numbers of cholinergic interneurons
have been observed in the striatum of schizophrenics (Holt et al.,
1999). Mice with VAChT deleted in striatum or knocked down
globally show no change in PPI (Guzman et al., 2011; Schmid et
al., 2011). Interestingly, PPI was impaired in the Vglut3 fl/fl;
Chat IRESCre/ mice, but not the Vglut3 fl/fl;ChatCre(G)/ mice,
which have elevated levels of VAChT and thus possibly increased
ACh release, suggesting that either glutamate or ACh signaling by
CINs is sufficient to maintain normal PPI.
Increased locomotor activity is usually reflected by an increase
in rearing behavior. However, VGLUT3KOmice do not demon-
strate a robust increase in rearing behavior at night, when
locomotor activity is greatly enhanced. Moreover, during the
daytime, bothKOandVglut3 fl/fl;Chat IRESCre/mice demonstrate
a decrease in rearing activity, which increases over repeated daily
exposures to the novel environment. Therefore it seems that loss
of VGLUT3 from cholinergic neurons mediates the suppression
of rearing; however, other modulatory systems, such as seroto-
nergic neurons, may also play a role (Amilhon et al., 2010).
Changes in MSN spine density are a common feature of ma-
nipulations that alter DA levels, for example, with repeated co-
caine use or in Parkinson’s disease. Here, we show that the MSN
spine density changes in concert with the circadian cycle. Spines
are increased in the dorsal and ventral striatum during the night,
when DA levels are elevated, and then return to baseline levels
during the day. Electrophysiological recordings show that the
enhanced spines are likely immature, consistent with their dy-
namic nature. Repeated cocaine administration increases the for-
mation of unstable dendritic spines in ventral MSNs, which
contain only NMDA and not AMPA receptors and are thus re-
ferred to as silent synapses (Huang et al., 2009; Brown et al., 2011;
Lee and Dong, 2011; Zhang et al., 2012; Lee et al., 2013). A sub-
sequent long-term absence of cocaine triggers silent synapses to
mature. It thus seems possible that the circadian-dependent in-
crease in DA in the VGLUT3 KO promotes the formation of
transient, immature synapses that never experience the right con-
ditions to mature.
One of ourmost striking findings is the absence ofmotor deficits
in VGLUT3 KO mice in a model of Parkinson’s disease. The
Vglut3 fl/fl;Chat IRESCre/micedidnot showthis effect, indicating that
the loss of VGLUT3 from cholinergic neurons is not sufficient to
ameliorate the motor symptoms. A likely candidate is instead the
increased DA release that occurs in the dorsal striatum of the global
KO during the waking cycle, although, curiously, motor behaviors
were also normal during the day.DAdepletion is known to produce
a decrease in MSN spine density that is compensated for by an in-
crease in the strength of cortical and thalamic glutamatergic inputs
(Villalba and Smith, 2013). It is thus intriguing to speculate that the
increased density of immature spines in the global KO is translated
intoan increase inmature spinesuponDAdepletion, thusproviding
a mechanism for the improved motor symptoms throughout the
circadian cycle.
The VGLUT3 KO mice also showed a marked attenuation of
L-dopa dyskinesias. A number ofmechanisms have been reported
to attenuate this unwanted motor behavior, including the abla-
tion and inhibition of striatal cholinergic interneurons (Won et
al., 2014; Lim et al., 2015), as well as disruption of D1 MSN
signaling with a conditional KO of DARPP-32 (Bateup et al.,
2010). Our findings show a trend toward a contribution by











































Vglut3 fl/fl; Chat Cre(G)/ N.E. N.T. N.T. N.T. Increased N.T. N.T. N.E. N.T. N.T.
Results are indicated as “increased” or “decreased” and are defined as a difference in amplitude, value, or frequency compared to control littermates. “night” or “day” indicates the limb of the circadian cyclewhen the phenotype occurs, and
some occur across the circadian cycle (night/day). If not specified, mice were tested during the day.
N.E.	 no significant effect of genotype observed; N.T.	 not tested.
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VGLUT3 expressed by CINs, but additional work is required to
fully understand the contribution of CIN-mediated signaling and
other VGLUT3-mediated signaling mechanisms to the develop-
ment and expression of LID.
In conclusion, our work here shows that VGLUT3 profoundly
regulates the activity of the midbrain DA system in a circadian-
dependentmanner. Thismodulationwill have a broad impact on
behavior because the circadian-dependent regulation of the basal
ganglia affects many aspects of brain function, including addic-
tion, psychiatric conditions, andmovement disorders (Edgar and
McClung 2013). In addition, the development of mice with a
cholinergic-specific deletion of VGLUT3 now allows us to rule
out the prevailing hypothesis that VGLUT3 in CINs affects DA
release in the dorsal striatum and baseline locomotor activity.
Finally, we demonstrate that the transporter strongly influences
mechanisms of neural plasticity that underlie motor deficits and
L-dopa-mediated dyskinesias in a Parkinson’s disease model.
These novel findings open new avenues for further experimental
investigation and the development of better treatment options.
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